The integration of advanced technologies like AI, machine learning, and CRISPR/Cas9 is streamlining the discovery and development of new drugs and therapies. With the global biotechnology market expected to reach $5.25 trillion by 2030, these technologies are making research and development processes more precise and efficient, heralding a new era of medical breakthroughs.

Given these positive trends, investors are showing keen interest in biotech stocks, as evidenced by the 6.9% return of the iShares Biotechnology ETF over the past year. Among the standout companies in this buoyant market are BioMarin Pharmaceutical Inc., Illumina, Inc., and Harmony Biosciences Holdings, Inc., all of which boast a B (Buy) rating in our proprietary POWR Ratings system.

BioMarin Pharmaceutical Inc. stands out for its impressive EBIT and EBITDA margins, significantly outperforming industry averages. The company's recent financial performance, with a 20% year-over-year revenue increase in the latest fiscal quarter, highlights its robust growth trajectory. $BMRN $HRMY $ILMN

https://stocknews.com/news/ilmn-bmrn-hrmy-3-b-rated-biotech-stocks-to-boost-your-bottom-line/